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Abstract
Background:  Given the growing population of cardiac surgery patients with impaired
preoperative cardiac function and rapidly expanding surgical techniques, continued efforts to
improve myocardial protection strategies are warranted. Prior research is mostly limited to either
large animal models or ex vivo preparations. We developed a new in vivo survival model that
combines administration of antegrade cardioplegia with endoaortic crossclamping during
cardiopulmonary bypass (CPB) in the rat.
Methods: Sprague-Dawley rats were cannulated for CPB (n = 10). With ultrasound guidance, a
3.5 mm balloon angioplasty catheter was positioned via the right common carotid artery with its
tip proximal to the aortic valve. To initiate cardioplegic arrest, the balloon was inflated and
cardioplegia solution injected. After 30 min of cardioplegic arrest, the balloon was deflated,
ventilation resumed, and rats were weaned from CPB and recovered. To rule out any evidence of
cerebral ischemia due to right carotid artery ligation, animals were neurologically tested on
postoperative day 14, and their brains histologically assessed.
Results: Thirty minutes of cardioplegic arrest was successfully established in all animals. Functional
assessment revealed no neurologic deficits, and histology demonstrated no gross neuronal damage.
Conclusion: This novel small animal CPB model with cardioplegic arrest allows for both the study
of myocardial ischemia-reperfusion injury as well as new cardioprotective strategies. Major
advantages of this model include its overall feasibility and cost effectiveness. In future experiments
long-term echocardiographic outcomes as well as enzymatic, genetic, and histologic
characterization of myocardial injury can be assessed. In the field of myocardial protection, rodent
models will be an important avenue of research.
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Background
Although considerable progress has been made in surgical
techniques and other perioperative management to allow
for the majority of patients to undergo cardiac surgery
without significant mortality, more than 25% of this sur-
gical population may still experience substantial morbid-
ity related to adverse cardiovascular events. These include
prolonged contractile dysfunction (stunning), myocardial
infarction, low-output syndromes, and overt ventricular
failure, all resulting in prolonged intensive care unit stay
and reduced functional capacity at discharge, and ulti-
mately contribute to overall mortality [1,2]. Mortality
after perioperative myocardial infarction is 40–50% [3].
The etiology of myocardial dysfunction following cardiac
surgery is multifactorial but frequently involves perioper-
ative myocardial ischemia reperfusion injury [4].
Since the advent of cardiopulmonary bypass (CPB), cardi-
oplegic arrest has been an essential component of cardiac
surgery but remains associated with ischemia-reperfusion
injury to the myocardium [5-7]. As the population ages
and percutaneous coronary interventions have become a
standard therapy, patients referred for cardiac surgery gen-
erally present with a higher risk for perioperative cardio-
vascular complications [8,9]. These complications are
primarily due to increased comorbidities and more com-
plex surgical interventions resulting in the need for more
prolonged aortic crossclamp and CPB times, all making
optimized myocardial protection strategies an essential
component of cardiac surgery procedures. Experimental
efforts to better understand the underlying mechanism
associated with postoperative myocardial reperfusion
injury and to improve established myocardial protection
protocols have been limited to either costly large animal
models or ex vivo heart preparations [10-12]. The use of
normothermic cardioplegia solutions has shown benefi-
cial results, but research is limited and principally relies
on isolated heart models [13-15]. However, these models
do not facilitate research on long-term effects of myocar-
dial reperfusion injury or novel therapeutic interventions.
To advance the field, additional research in a suitable
rodent model with good survivability appears to be war-
ranted. Such a model would not only allow to further elu-
cidate mechanisms of adverse myocardial outcomes
following cardioplegic arrest but also permits the charac-
terization of genetic, proteomic, and histologic changes as
well as long-term functional outcomes in response to
injury and therapy. It might also facilitate further research
aiming to optimize current cardioprotective strategies in
vivo  and facilitate myocardial gene delivery studies
[16,17].
Based on an existing beating-heart model of CPB in the rat
[18], we developed a novel in vivo survival model that
allows administration of antegrade cardioplegia and
endoaortic crossclamping. To rule out any gross neurolog-
ical damage due to cannulation of the right carotid artery,
a functional assessment and histological evaluation of the
brains was performed.
Methods
The study was approved by the Duke University Animal
Care and Use Committee, and all procedures met the
National Institutes of Health (NIH) guidelines for animal
care [19].
Male 400–425 g Sprague-Dawley rats (Charles River Labs,
Wilmington, MA, USA) were housed two per cage under a
12-hour light-dark cycle with food and water available ad
libitum.
Anesthesia, surgical preparation, cardiopulmonary bypass, 
and neurological assessment
Fasted rats (n = 10) were anesthetized with 5% isoflurane
in 50% O2 in a plastic induction box. After orotracheal
intubation with a 14G cannula (Insyte BD Medical,
Sandy, UT), the animals were mechanically ventilated
(Harvard Model 687, Harvard Apparatus, Holliston, MA)
60 breaths·min-1 with FiO2 0.6 while maintaining a nor-
mal arterial carbon dioxide tension. The maximal airway
pressure did not exceed 20 mmH2O. During subsequent
surgical preparation, anesthesia was maintained with 1.5–
2.0% isoflurane. A needle thermistor was inserted in the
left temporal muscle adjacent to the skull to measure
pericranial temperature. With both forced-air and surface
heating systems, temperature during surgery was control-
led at 36°C when not on CPB, during CPB, and cardiople-
gic arrest at 34°C. Towards the end of, and after CPB,
temperature was controlled at 37°C. Electrocardiogram
(EKG) electrodes were placed on both front paws and left
hind paw.
Surgical preparation consisted of cannulation of the tail
artery with a 20 G catheter (Insyte BD Medical, Sandy,
UT), which served as the arterial inflow cannula for the
CPB circuit. 150 IU porcine heparin and 5 μg fentanyl
were administered after placement of this first cannula.
Mean arterial blood pressure was monitored via the super-
ficial caudal epigastric artery, which was cannulated with
polyethylene tubing (PE-10 Intramedic Tubing, Becton-
Dickinson, Sparks, MD). A 3.5 mm angioplasty balloon
catheter (Sprinter®  OTW, Medtronic Inc, Minneapolis,
MN) was retrogradely inserted into the ascending aorta
via the right common carotid artery and positioned, under
ultrasound guidance (SONOS 7500, Philips Medical Sys-
tems, Andover, MA), with its tip just above the aortic valve
(Figure 1). This catheter served as an endoaortic cross-
clamp during the experiment, comparable with PortAc-
cess™ surgery as performed in humans [20]. A multi-
orificed 4.5 Fr catheter (modified Desilets-Hoffman Cath-Journal of Cardiothoracic Surgery 2008, 3:51 http://www.cardiothoracicsurgery.org/content/3/1/51
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eter, Cook, Bloomington, IN) was advanced through the
right external jugular vein into the right atrium and served
as a conduit for venous outflow. Repeat injections of 150
IU porcine heparin and 5 μg fentanyl were administered,
and CPB was initiated. In addition, 0.2 mg pancuronium
was administered prior to CPB. Muscle relaxation was
used to prevent spontaneous ventilation that often inter-
feres with venous return due to movement of the medias-
tinal structures relative to the venous outflow cannula.
The CPB circuit (Figure 2) consisted of a 4 ml Plexiglas
venous reservoir, a roller pump (Masterflex; Cole-Parmer
Instrument Co., Vernon Hills, IL), and a custom-designed
small-volume oxygenator (M. Humbs, Valley, Germany).
The 4 ml priming volume oxygenator was built of two
Plexiglas shells (12.8 cm × 12.8 cm × 2.7 cm) that carry a
sterile, disposable three layer hollow fiber membrane pro-
viding a surface area for gas exchange of 558 cm2 [18,21].
To prevent excessive heat loss, one of the shells had an
integrated heat exchanger. An in-line flow probe (2N806
probe and T208 flowmeter, Transonics Systems Inc., Ith-
aca, NY) was used to continuously measure CPB flow. The
entire circuit was primed with 10 mL of 6% hetastarch
(Hextend, Hospira Inc, Lake Forest, IL). All parts were
connected through single use silicone tubing. During
CPB, a flow rate of 150 mL·kg-1·min-1 was maintained,
and an average of 3 mL of hetastach was added to com-
pensate losses and extravasation. At the start of CPB,
frequency of ventilation was lowered to 30 min-1, and
0.5–1% isoflurane was administered through the oxygen-
ator with 70% oxygen and additional CO2 as needed (α
stat blood gas management). After 15 min of CPB, the
endoaortic clamp was quickly inflated while concomi-
tantly 0.5 ml cardioplegia was infused via an infusion
pump at a rate of 200 mL·hr-1 through the central lumen
of the angioplasty catheter. Cardioplegia solution con-
sisted of 4 parts of standard undiluted adult cardioplegia
induction solution (5% dextrose in 0.225% NaCl (655
mL·L-1) potassium chloride (95 mEq·L-1), tromethamine
(238 mL·L-1), and citrate-phosphate-dextrose (CPD)
solutions (60 mL·L-1), and 1 part esmolol 10 mg·ml-1.
Ventilation was discontinued. Cardioplegic arrest was
confirmed both by ultrasound and electrocardiographi-
cally. The CPB flow rate was adjusted as needed to main-
tain a constant venous reservoir blood level. At 15 min of
arrest, a second dose of 0.4 mL of cardioplegia was admin-
istered to uphold the arrest. After 30 min of cardioplegic
arrest, the balloon was deflated and removed and ventila-
tion restarted at a slower rate of 35 min-1 and FiO2 of 0.7.
CPB was maintained for another 30 min to allow for
rewarming of the animals. After discontinuation of CPB,
the ventilatory rate was raised to 60 min-1. The venous
cannula was removed, and the incision closed. During the
entire experiment, mean arterial pressure was maintained
above 45 mmHg, with the use of small doses of phenyle-
phrine if necessary. After cessation of CPB, the remaining
blood left in the CPB circuit was centrifuged for 5 min at
3000 rpm, and the supernatant discarded. Two mL of the
remaining red blood cell concentrate was then re-infused.
The animals were ventilated for another 60 min, after
which the remaining cannulae were removed, and the
wounds closed. The rats recovered in a warmed and oxy-
gen-enriched environment for at least 12 hr prior to return
to their home cages. Blood gas analysis was performed
before the start of CPB, at 15 min of CPB, at 15 min of
arrest, at the end of 30 min arrest, at the end of the total
of 75 min of CPB, and at 1 hr post CPB, using an IL-GEM
Premier 3000 blood gas analyzer (Global Medical Instru-
mentation, Ramsey, MI).
During the first 14 postoperative days, the animals were
checked daily for their overall well-being and wound heal-
ing. To determine if any neurologic injury occurred
(because of intraoperative usage and postoperative liga-
tion of the right common carotid artery), neurological
function was assessed at day 14, using a previously estab-
lished neurological scoring system [22]. In brief, it was
derived by evaluating four different functions (general sta-
tus, simple motor deficit, complex motor deficit, and sen-
sory deficit). The score given to each animal was the sum
of all four individual scores: 0 was the best and 48 the
worst score possible [22].
Echocardiographic image of angioplasty balloon catheter  positioned near aortic valve Figure 1
Echocardiographic image of angioplasty balloon cath-
eter positioned near aortic valve. Green distance meas-
ure indicating a distance of 0.23 cm from tip of balloon 
catheter to aortic valve. AV = aortic valve, BC = tip of bal-
loon catheter, VC = multi-orificed venous cannula advanced 
into right atrium.Journal of Cardiothoracic Surgery 2008, 3:51 http://www.cardiothoracicsurgery.org/content/3/1/51
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TTC staining
On postoperative day 14, the animals were sacrificed by
inhalation of 5% isoflurane followed by decapitation. The
brains were serially sliced into 2 mm coronal sections with
the use of a brain matrix. Brain sections were immediately
incubated in TTC (2,3,5-Triphenyl-tetra-zolium-chlorid)
at 37°C for 20 minutes and subsequently stored in 10%
phosphate-buffered formalin to detect any focal cerebral
injury.
Results
Full cardioplegic arrest over 30 min was successfully
achieved in all animals. In two out of the ten animals, the
initial arrest after the induction bolus of cardioplegia was
incomplete as seen on the EKG. However, with a subse-
quent dose of 0.2 mL of cardioplegia, full arrest was
achieved. None of the animals received more than 0.9 mL
of cardioplegia in total. Following 30 min of cardioplegic
arrest, when the endoaortic balloon was deflated, sponta-
neous cardiac rhythm with frequencies identical as pre-
CPB resumed within seconds. Separation from CPB with-
out the use of inotropic agents was achieved in all ani-
mals.
Table 1 displays the physiologic parameters of all animals.
Because of the nature of CPB, rats demonstrated lower
MAP, higher PaO2 values, and lower hemoglobin concen-
trations during CPB as compared to baseline values.
Retransfusion of 2 ml of concentrated blood from the CPB
circuitry allowed the hemoglobin level to rise again. All
animals survived the postoperative period and underwent
neurological testing at day 14. Out of the 48 point maxi-
mum (worst) score, the animals scored 2.5 ± 1.4 points on
average, consistent with no neurological deficits. Histo-
logical assessment of the brain showed no infarcted areas
in any of the animals.
Schematic diagram of rat CPB apparatus and surgical preparation highlighting the aortic balloon catheter serving as endoaortic  crossclamp Figure 2
Schematic diagram of rat CPB apparatus and surgical preparation highlighting the aortic balloon catheter 
serving as endoaortic crossclamp. CPB = cardiopulmonary bypass.Journal of Cardiothoracic Surgery 2008, 3:51 http://www.cardiothoracicsurgery.org/content/3/1/51
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Discussion
Research focusing on cardioprotective strategies during
cardiac surgery has been hindered by the lack of a suitable
small animal model that would allow for complete cardi-
oplegic arrest with good survivability. Most previous
research was performed in isolated heart models
[10,14,15]. While these models allow investigating the
immediate effects of therapeutic interventions or different
cardioplegia solutions, they preclude the assessment of
long-term histological, biochemical, or functional out-
comes. Survival studies using dogs [13,23,24] or pigs [25]
have been performed but are limited due to sample size
and costs. Although a number of rat CPB models have
been described over the years [26-30], all of them were
resembling beating heart CPB, and none of them included
any form of aortic crossclamping and antegrade cardiople-
gia administration. To our knowledge, only one small ani-
mal cardioplegic arrest model has been described so far
[31]. In their paper, Günzinger et al. describe a rat model
in which cardioplegic arrest is achieved by injecting a car-
dioplegic solution into the aortic through a sternotomy
while at the same time the branchiocephalic trunk and
aortic arch are occluded by tourniquets. Blood loss during
the procedure is significant. Compared to our model, this
previously described model is not a survival model as it
includes full sternotomy (preferably avoided in small
four-legged animals), and carotid arteries and jugular
veins are cannulated. Therefore, we describe a novel in vivo
survival CPB model that allows minimal invasive admin-
istration of antegrade cardioplegia with endoaortic cross-
clamping with resulting cardioplegic arrest in rats.
Due to the excellent survivability and ease of postopera-
tive cardiac recovery, this model lends itself to the investi-
gation of genomic and proteomic changes as well as
histological alterations that can be assessed at any time
point and new therapeutic interventions aiming to opti-
mize cardioprotection. Over the last several years, sub-
stantial preclinical advances have been made in gene- or
cell-based therapies for myocardial protection and in res-
cue strategies for myocardial ischemia-reperfusion injury,
all aimed to employ different types of genes, vectors, and
delivery routes [32,33]. Among these, cardiac gene deliv-
ery methods with the use of CPB, in which the adenoviral
vector is administered following cardioplegic arrest, allow
prolonged myocardial exposure time to the adenoviral
vector and improved gene transfer [16,17]. We speculate
that the model described here will, therefore, facilitate
direct intracoronary administration of medications, gene
vectors, or cells and might even allow for ultrasound-
mediated gene transfer. Because exposure time and coro-
nary flow are major determinants of efficient intracoro-
nary delivery, complete cardioplegic arrest with negligible
coronary flow and long wash-in periods will likely opti-
mize delivery and limit extracardiac expression [16,17].
In the search for a suitable model to study novel cardio-
protective strategies, we adapted a rodent CPB model that
we had previously described and utilized [34,35]. In the
original description by Grocott et al.,[29] the smallest
available human oxygenator was used, which was largely
oversized for rodents. The model was later adapted, and a
small, appropriately sized rat oxygenator was developed
and inserted, thereby abolishing the need of donor blood
to prime the circuit and allowing effects of appropriately
sized CPB to be determined [18,36]. Careful positioning
of the venous outflow catheter allowed for optimal
venous drainage, and CPB flows consistent with a normal
cardiac output in rats could be achieved. The natural car-
diac rhythm, however, was unaltered, and pilot studies
indicated that when venous drainage was not optimal, the
heart continued to variably eject. Therefore, we adapted
Table 1: Physiologic parameters.
CPB
Baseline 15 CPB 15 arrest 30 arrest 75 CPB 1 h post
Weight (g) 419 (7.7)
Hematocrit (%) 41 (1) 27 (2) 28 (2.7) 29 (2.1) 29 (3) 33 (2)
Glucose (mg/dl) 100 (14) 136 (12)
Temperature (°C) 35.6 (0.6) 34.8 (0.6) 34.4 (0.5) 34.2 (0.4) 35.6 (0.7) 36.9 (0.5)
CPB flow (ml/min) 51 (5) 65 (9) 62 (11)
MAP (mmHg) 62 (7) 61 (5) 48 (5) 46 (5) 68 (15) 75 (8)
Arterial pH 7.42 (0.02) 7.42 (0.06) 7.46 (0.06) 7.43 (0.08) 7.38 (0.08) 7.38 (0.06)
PaC02 (mmHg) 40 (2) 35 (5) 34 (5) 36 (5) 42 (7) 41 (5)
Pa02 (mmHg) 208 (33) 366 (52) 348 (69) 325 (107) 308 (68) 285 (63)
HCO3
- (mmHg) 26.1 (1.6) 22.5 (1.4) 23.9 (2.1) 24.2 (1.8) 25.6 (2.0) 24.4 (3.0)
CPB = cardiopulmonary bypass
MAP = mean arterial pressure
PaC02 = Partial pressure of carbon dioxide
Pa02 = Partial pressure of oxygen
HC03 = Standard bicarbonateJournal of Cardiothoracic Surgery 2008, 3:51 http://www.cardiothoracicsurgery.org/content/3/1/51
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this model by inserting the smallest commercially availa-
ble angioplasty balloon catheter with a central lumen ret-
rogradely into the common carotid artery with the tip
carefully positioned just proximal to the aortic valve.
Inflation of the balloon resulted in effective aortic cross-
clamping, and concomitant administration of cardiople-
gia solutions through the lumen allowed for immediate
cardioplegic arrest confirmed by ultrasound and EKG.
The right common carotid artery provided direct access to
the ascending aorta, combining the correct vessel size with a
relatively short distance to the aortic valve. A full sternotomy
and direct cannulation of the heart is very invasive and
would likely cause increased mortality. At the end of the
experiment when the catheter is removed, the right com-
mon carotid artery is permanently ligated. Although it has
been described that ligation of one carotid artery in young
healthy rats is without consequences [37], the exclusion of
gross neurological or histological abnormalities appeared to
be justified before utilizing or developing this model fur-
ther. The absence of neurological deficits screened with a
48-point neurologic scoring system [22], and the absence of
any signs of cerebral infarction following TTC staining of the
brains 14 days after surgery support this prior work. Because
the scope of the current work was purely to develop the
experimental technique and demonstrate the technical fea-
sibility of achieving 30 min of full cardioplegic arrest in rats
with good survivability, we did not quantify cardiac func-
tion postoperatively. However, the model described here
permits comprehensive perioperative echocardiographic
evaluation of cardiac function in future studies. Another
major advantage of this model is its minimal invasiveness
(closed chest), and that it can be performed by one operator
only, thus facilitating higher experimental throughput at
lower costs. As an indication, the disposable membrane for
the oxygenator costs $65, the Plexiglas parts of the CPB sys-
tem (venous reservoir, oxygenator shell) can be re-used after
vigorous cleaning and sterilizing while the CPB tubing was
discarded after each bypass run. After extensive training, a
perioperative mortality less than 10–15% can be achieved.
The model has several potential pitfalls. The endoaortic
catheter requires exact and precise positioning close to the
aortic valve. Ultrasonographic imaging is essential for
positioning of the angioplasty catheter as well as assessing
the cardioplegic arrest. When the catheter is not posi-
tioned optimally, incomplete arrest will be the result, and
the balloon might even damage the brachiocephalic trunk
(too high) or the left ventricle (too deep). If the injection
of cardioplegia is executed too forcefully, dilatation of the
left ventricle will occur. Measuring the pressure at the tip
of the balloon catheter combined with the use of an infu-
sion pump solves this issue. Use of the manufacturer's
inflation device prevents overinflation of the endoaortic
balloon. After failed cardioplegic arrest on the first
attempt, repeated small doses of cardioplegia will result in
complete arrest. Although we did not measure potassium
in these animals, earlier pilot experiments revealed that
hyperkalemia does not occur with the dosing regimen
used in this protocol. Immediate return to regular sinus
rhythm at preoperative rates following deflation of the
endoaortic balloon and restoration of preoperative hemo-
dynamics present further indirect evidence that the cardi-
oplegic regimen did not result in hyperkalemia.
As this work was entirely focused on developing the min-
imal invasive technique to accomplish CPB with cardio-
plegic arrest, we have not yet systematically investigated
possible definite outcomes. However, study endpoints
such as technical feasibility, effective cardioplegia, and
survival were successfully demonstrated. The model
described will not only facilitate further research to eluci-
date mechanisms of myocardial reperfusion injury fol-
lowing cardioplegic arrest and CPB but also to evaluate
novel approaches to improved myocardial protection.
Due to its minimal invasiveness and ease of recoverabil-
ity, short- and long-term effects of constituents of cardio-
plegia, duration of cardioplegic arrest, CPB time, and
potentially also direct gene transfer on myocardial func-
tion and histological outcomes can be assessed better than
in isolated heart models. In addition, the model allows for
the investigation of unique animal strains with varying
susceptibility to myocardial injury depending on either
their genetic background (consomic) or preexisting dis-
ease (e.g., diabetes, old age, hypertension).
Conclusion
This novel small animal CPB model with cardioplegic
arrest allows for both the study of myocardial ischemia-
reperfusion injury as well as the evaluation of new cardio-
protective strategies. Major advantages of this model
include its overall feasibility and cost effectiveness. In the
field of myocardial protection, rodent models will remain
an important avenue of research. Models such as the one
described here will likely be utilized to not only assess
longer-term functional outcomes but also characterize the
enzymatic, genetic, and histologic response to myocardial
injury and protective strategies.
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